Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Liabilities and Shareholders Equity (2016 - 2025)

Cytosorbents' Liabilities and Shareholders Equity history spans 15 years, with the latest figure at $44.2 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $44.2 million for Q4 2025, down 6.73% from a year ago — trailing twelve months through Dec 2025 was $188.7 million (down 3.56% YoY), and the annual figure for FY2025 was $44.2 million, down 6.73%.
  • Liabilities and Shareholders Equity for Q4 2025 was $44.2 million at Cytosorbents, down from $45.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $98.2 million in Q2 2021 to a low of $44.2 million in Q4 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $53.2 million (2023), against an average of $62.3 million.
  • The sharpest move saw Liabilities and Shareholders Equity surged 99.34% in 2021, then tumbled 34.5% in 2022.
  • Year by year, Liabilities and Shareholders Equity stood at $89.5 million in 2021, then fell by 29.37% to $63.2 million in 2022, then dropped by 16.25% to $53.0 million in 2023, then decreased by 10.55% to $47.4 million in 2024, then dropped by 6.73% to $44.2 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $44.2 million, $45.8 million, and $48.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.